GSK Sells Haleon Shares Valued Around $1.24 Billion Through Discounted Placing
Provided by
Dow Jones
By Michael Susin
GSK said it has sold a stake in Haleon valued around 978 million pounds ($1.24 billion), reducing its stake in the consumer-healthcare business to around 4.2%.
The British pharmaceutical giant said Wednesday that it has sold 300 million Haleon shares at an offer price of 326 pence a share. This represents a discount of 2.3% from Tuesday's closing price of 333.6 pence prior to the announcement.
U.S. pharma giant Pfizer also holds a 32% stake in Haleon, which was spun out of GSK and Pfizer's consumer-healthcare business.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
January 17, 2024 02:29 ET (07:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
10 Top-Performing Dividend Stocks
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters